Amphastar Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Amphastar just signed a big deal, details TBD.

AI Summary

On September 15, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counterparty, or any associated financial terms.

Why It Matters

This filing indicates a significant new contract or partnership for Amphastar Pharmaceuticals, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Registrant

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share AMPH The Nasdaq Stock Mar
• $2.8 m — e Company will not exceed approximately $2.8 million, with payments adjusted based on
• $0.3 million — e Company will pay Hanxin approximately $0.3 million on the Effective Date. Any additional w

Filing Documents

• amph-20250915x8k.htm (8-K) — 51KB
• 0001297184-25-000054.txt ( ) — 160KB
• amph-20250915.xsd (EX-101.SCH) — 4KB
• amph-20250915_lab.xml (EX-101.LAB) — 15KB
• amph-20250915_pre.xml (EX-101.PRE) — 10KB
• amph-20250915x8k_htm.xml (XML) — 5KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On September 15, 2025 (the "Effective Date") Amphastar Pharmaceuticals, Inc. (the "Company"), entered into a contract research agreement (the "Agreement") with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. ("Hanxin"). Pursuant to the Agreement, Hanxin will develop Recombinant Peptide Research Cell Banks ("RCBs") for the Company and license the RCBs to the Company subject to a fully paid, exclusive, perpetual, transferable, sub-licensable license worldwide (the "Transaction"). The RCBs will be used by the Company to make Master Cell Banks for one of its product candidates, AMP-107. Hanxin is obligated to keep the Company informed of progress of development and research as set forth in the Scope of Work, which is incorporated as Appendix A to the Agreement (the "Scope of Work"). Per the terms of the Agreement, all title to the RCBs developed, prepared and produced by Hanxin in conducting research and development will belong to the Company. The Company will also own any confidential and proprietary information, technology regarding development and manufacturing of the RCBs, which include, but are not limited to, engineering, scientific and practical information and formula, research data, design, and procedures to develop and manufacture the RCBs, in use or developed by Hanxin. Each of the Company and Hanxin have made customary representations, warranties and covenants in the Agreement. The term of the Agreement is three years from the Effective Date. Payments under the agreement will be made in Chinese yuan. The total cost of the Agreement to the Company will not exceed approximately $2.8 million, with payments adjusted based on actually currency exchange rates. The Company will pay Hanxin approximately $0.3 million on the Effective Date. Any additional work or changes to the Scope of Work requested by the Company will be charged by Hanxin to the Company on a cost plus basis, plus any applicable taxes. Any

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMPHASTAR PHARMACEUTICALS, INC. Date: September 18, 2025 By: /S/WILLIAM J. PETERS William J. Peters Chief Financial Officer, Executive Vice President and Treasurer